CEO Martine Rothblatt recently traded two times in UTHR, both times increasing her position in the company. On 12/30/2011, she bought 11,823 shares of the company at an average price of $43.92. The price of the stock has since increased by 3.42%.
However, other insiders are decreasing their shares in the company. President and COO Roger Jeffs sold 5,000 shares of the company on 2/3/2012, while Executive Vice President and General Counsel Paul Mahon sold 72,000 shares at an average price of $50. Director Christopher Patusky sold off 7,500 shares over the course of two months in early 2012.
CEO Martine Rothblatt works in the field of communication satellite law and is also engaged in various life science projects such as the Human Genome Project. She was the second highest-compensated executive in the District of Columbia in 2007. She graduated from UCLA and previously worked as an attorney.
Richard Perry bought 15,300 shares of UTHR in the quarter that ended on 03/31/2012, which is 0.035% of the $2.08 billion portfolio of Perry Capital. Joel Greenblatt owns 165,063 shares as of 03/31/2012, an increase of 82.68% from the previous quarter. This position accounts for 0.68% of the $1.15 billion portfolio of Gotham Capital. Edward Owens owns 1,787,000 shares as of 03/31/2012, which accounts for 0.4% of the $20.91 billion portfolio of Vanguard Health Care Fund.
Revenue per share for UTHR increased at an average of 46.1% per year over the past 10 years, 29.2% over the past five years, and 29.9% over the past 12 months. Earnings per share were historically mostly positive, with three out of the last ten years reporting negative profits. UTHR holds about $400 million in cash, but has $71.45 million in long-term debt. About 80% of the company’s total current assets are in cash. UTHR has a predictability rating of 1 star.